Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2‐positive breast cancer: a meta‐analysis of randomized controlled trials

This meta‐analysis compared the efficiency and safety of lapatinib and trastuzumab, alone or in combination, administered with neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. For dichotomous variables, the relative risk ratio (RR) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Yong, Guo, Wen Wen, Huang, Qian, Zhang, Pei, Zhang, Long‐Zhen, Jiang, Guan, Tian, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224855/
https://www.ncbi.nlm.nih.gov/pubmed/27882700
http://dx.doi.org/10.1002/cam4.963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224855/
https://www.ncbi.nlm.nih.gov/pubmed/27882700
http://dx.doi.org/10.1002/cam4.963

Ejemplares similares